Immunogenic Cell Death: An Emerging Target in Gastrointestinal Cancers.
DAMPs
HMGB-1
colorectal cancer
gastric cancer
gastrointestinal cancers
hepatocellular carcinoma
immunogenic cell death
pancreatic cancer
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
28 09 2022
28 09 2022
Historique:
received:
05
09
2022
revised:
23
09
2022
accepted:
25
09
2022
entrez:
14
10
2022
pubmed:
15
10
2022
medline:
18
10
2022
Statut:
epublish
Résumé
Immunogenic cell death (ICD) is a regulated form of cell death that induces the activation of both innate and adaptive immune responses through the release of damage-associated molecular patterns (DAMPs) and their subsequent recognition by pattern-recognition receptors (PRRs), generating specific CD8+ T lymphocytes. Thus, ICD inducers (such as certain chemotherapeutic agents, targeted therapies, radiation, and oncolytic viruses) could become a potential cancer treatment by providing antitumour immunity and cancer vaccination. Moreover, their combination with immunotherapy, especially with immune checkpoint inhibitors, could overcome the immunosuppressive tumour microenvironment that characterises certain cancers, including gastrointestinal cancers. This review will provide insights into the role of ICD induction in colorectal, gastric, pancreatic, and hepatocellular carcinomas. Specifically, we will discuss the main mechanisms involved in ICD, their potential application in gastrointestinal cancer treatment, and the latest clinical trial updates.
Identifiants
pubmed: 36230995
pii: cells11193033
doi: 10.3390/cells11193033
pmc: PMC9563749
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Nat Med. 2016 Jun;22(6):624-31
pubmed: 27135741
N Engl J Med. 2020 Dec 3;383(23):2207-2218
pubmed: 33264544
Oncoimmunology. 2014 Apr 25;3:e28518
pubmed: 25071979
Nat Rev Clin Oncol. 2019 Jun;16(6):356-371
pubmed: 30705439
Int Rev Cell Mol Biol. 2020;350:63-118
pubmed: 32138904
Lancet. 2021 Jul 3;398(10294):27-40
pubmed: 34102137
J Immunother Cancer. 2021 Sep;9(9):
pubmed: 34593621
J Immunother Cancer. 2022 Mar;10(3):
pubmed: 35361730
Science. 2015 Nov 20;350(6263):972-8
pubmed: 26516201
Lancet Oncol. 2022 May;23(5):659-670
pubmed: 35427471
Lancet Oncol. 2022 Jul;23(7):876-887
pubmed: 35636444
Autophagy. 2013 Sep;9(9):1292-307
pubmed: 23800749
Lancet Oncol. 2021 Feb;22(2):198-211
pubmed: 33476593
J Inflamm (Lond). 2021 Jun 10;18(1):23
pubmed: 34112202
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Nature. 2021 Dec;600(7890):727-730
pubmed: 34912120
Blood. 2007 Jun 1;109(11):4839-45
pubmed: 17299090
Nat Rev Cancer. 2021 May;21(5):298-312
pubmed: 33750922
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Clin Transl Oncol. 2021 Jan;23(1):110-121
pubmed: 32661823
Nat Rev Mol Cell Biol. 2020 Sep;21(9):501-521
pubmed: 32424334
Cancers (Basel). 2019 Oct 19;11(10):
pubmed: 31635070
Nat Rev Immunol. 2009 May;9(5):353-63
pubmed: 19365408
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
J Immunother Cancer. 2020 Nov;8(2):
pubmed: 33172883
J Clin Oncol. 2019 Mar 1;37(7):537-546
pubmed: 30620668
Oncogene. 2010 Jan 28;29(4):482-91
pubmed: 19881547
J Clin Oncol. 2022 Jan 10;40(2):127-137
pubmed: 34818112
Nat Med. 2007 Sep;13(9):1050-9
pubmed: 17704786
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
Cancer Immunol Res. 2020 Jan;8(1):94-107
pubmed: 31719057
J Immunother. 2010 Oct;33(8):828-33
pubmed: 20842054
J Exp Med. 2005 Dec 19;202(12):1691-701
pubmed: 16365148
Cell Res. 2021 Jan;31(1):5-16
pubmed: 32733014
Sci Rep. 2021 Jun 10;11(1):12264
pubmed: 34112882
Sci Transl Med. 2019 Oct 23;11(515):
pubmed: 31645452
Nat Immunol. 2022 Apr;23(4):487-500
pubmed: 35145297
Anticancer Res. 2016 Sep;36(9):4381-9
pubmed: 27630273
Biomaterials. 2016 Sep;102:187-97
pubmed: 27343466
Nat Rev Clin Oncol. 2021 Sep;18(9):591-602
pubmed: 33976418
Lancet Oncol. 2022 Sep;23(9):1133-1144
pubmed: 36055304
Cell Death Differ. 2018 Aug;25(8):1375-1393
pubmed: 29358668
Cell Death Differ. 2014 Dec;21(12):1825-37
pubmed: 25012502
Nat Commun. 2017 Nov 27;8(1):1811
pubmed: 29180759
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
Cell Oncol (Dordr). 2020 Dec;43(6):1203-1214
pubmed: 32797385
Front Immunol. 2022 May 31;13:876291
pubmed: 35711414
Cell Death Dis. 2019 Aug 2;10(8):578
pubmed: 31371700
Lancet Oncol. 2019 Oct;20(10):1370-1385
pubmed: 31427204
EMBO J. 2021 Jul 1;40(13):e108130
pubmed: 34121201
Nat Med. 2022 Jun;28(6):1167-1177
pubmed: 35662283
Int J Cancer. 2013 Dec 1;133(11):2619-30
pubmed: 23729200
Sci Transl Med. 2018 Sep 19;10(459):
pubmed: 30232229
J Immunother Cancer. 2021 Sep;9(9):
pubmed: 34479922
Cancers (Basel). 2021 Mar 11;13(6):
pubmed: 33799527